RxDoctor Payments DataLook up a doctor →

Michael Chen, DO

Pain Medicine · Sandy, UTNPI 1487711123

Payments from drug & device makers

$10,532in general payments, 2019–2025

Across 503 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Pfizer$853
  • Boston Scientific$494
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$1,20011%
  • Speaking & faculty fees$3353%
  • Travel & lodging$1,66316%
  • Food & beverage$7,33070%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,532 in reported general payments places this provider in the 80th percentile of 61 pain medicine providers in Utah.

See all pain medicine providers in Utah

Medicare billing

Part B allowed, 2024
$276,901
Medicare patients
208
Services billed
7,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate82$59,628
ForteoTeriparatide13$54,653
Nurtec OdtRimegepant Sulfate20$26,967
MovantikNaloxegol Oxalate62$26,639
Nucynta ErTapentadol Hcl12$20,204
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen371$16,220
Oxycodone Hcl597$13,509
HorizantGabapentin Enacarbil11$10,742
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen303$10,111
Aimovig AutoinjectorErenumab-Aooe12$9,086
Butorphanol Tartrate13$8,070
Morphine Sulfate ErMorphine Sulfate237$6,568
SymproicNaldemedine Tosylate11$6,515
Buprenorphine14$4,179
Gabapentin200$3,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er$1,178$79,83294 claims
Lilly USA, LLCForteo$69$54,65313 claims
PfizerNurtec Odt$853$26,96720 claims
Redhill Biopharma Inc.Movantik$54$26,63962 claims
Arbor Pharmaceuticals, Inc.Horizant$54$10,74211 claims
Shionogi IncSymproic$28$6,51511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 61 pain medicine providers in Utah.

Other pain medicine in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →